LNAI News & Events

Lunai Bioworks' (LNAI) wholly owned subsidiary BioSymetrics and BrainStorm (BCLI) announced a strategic collaboration and Letter of Intent to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the LouLou Foundation. The collaboration combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation platform with BrainStorm Therapeutics' proprietary human-derived organoid systems to create an integrated translational engine for neurology drug discovery. The companies intend to generate high-confidence therapeutic programs designed for pharmaceutical partnering, licensing, and downstream development. Initial efforts will focus on rare genetic epilepsies and neurodegenerative diseases, including Parkinson's disease. As part of the collaboration, the companies are integrating BrainStorm's Parkinson's disease midbrain organoid foundation model with BioSymetrics' proprietary analysis of the Parkinson's Progression Markers Initiative dataset, to identify progression-associated biomarkers and high-confidence therapeutically actionable targets. The program is intended to support precision medicine strategies and accelerate the development of differentiated CNS therapeutics.

Lunai Bioworks and Geneial, a precision medicine data infrastructure and patient engagement company, announced that BioSymetrics, a wholly owned Lunai subsidiary, has signed a Letter of Intent, or LOI, with Geneial to pursue a strategic collaboration in rare neurological disorders. The collaboration is designed to support rare disease research and advocacy groups in converting fragmented, patient-generated data into actionable drug development programs, including the creation and activation of trial-ready patient cohorts that can support pharmaceutical partnerships. Under the proposed collaboration, BioSymetrics and Geneial plan to: integrate and standardize patient-led rare disease datasets; identify defined patient subgroups for clinical development; generate actionable insights to support therapeutic programs; enable the activation of trial-ready cohorts for pharma and biotech engagement. The companies expect to pursue commercial partnerships enabled by these efforts. The initial focus will include select rare neurodevelopmental disorders, with the goal of building scalable programs that can expand over time. The LOI is non-binding.